Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

mRNA vaccines and therapeutics market forecast 2019-2029

4 views

Published on

Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy

Published in: Health & Medicine
  • Be the first to like this

mRNA vaccines and therapeutics market forecast 2019-2029

  1. 1. www.visiongain.com/industries/pharma Page69 mRNA Vaccines and Therapeutics Market Forecast 2019- 2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy Figure 7.5 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2029 Source: Visiongain, 2019 7.2.1 Bioengineered Vaccine: Market Forecast, 2019-2029 Genetically engineered subunit vaccines are more expensive to produce than conventional vaccines, as the antigen needs to be purified to a higher standard than older conventional vaccines required. As it would be considered a new product, each vaccine must also be subjected to extensive testing and review by the FDA. This is time and money expensive for a company and is unnecessary if there is already a licensed product on the market. Despite the high promise of recombinant subunit vaccines, they present some potential limitations. Recombinant subunit vaccines, besides being less reactogenic, tend to be less immunogenic than their conventional counterparts. These vaccines may be attributed to a higher degree of purity than was traditionally done for a previous generation of licensed subunit vaccines. This can be attributed to the higher purity of these vaccines than was traditionally done for an earlier generation of licensed subunit vaccines. Recombinant subunit vaccines may also be too well-defined because they consist of a single antigen. Conventional vaccines, on the other hand, contain trace amounts of other antigens that can help to give infectious agents immunity that is more solid than a monovalent vaccine could provide. By creating recombinant vaccines consisting of multiple antigens from the same pathogen, this problem can be minimized if necessary. These issues are less of a concern with a live attenuated vaccine, as these vaccines are less expensive, require less manufacturing steps, and after a single dose elicit long-lived immunity. 13.20% 21.20% 18.00% 17.00% 20.50% 10.10% Bioengineered Vaccine Gene Therapy (Gene silencing/suppression) Gene Transcription (Protein Generation) Cell Therapy Monoclonal Antibody Others
  2. 2. www.visiongain.com/industries/pharma Page102 mRNA Vaccines and Therapeutics Market Forecast 2019- 2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy The Spanish mRNA Vaccines and Therapeutics Market accounted for $0.08 bn in 2018 and is expected to reach $0.25 bn by 2029 with a CAGR of 10.48% during 2019-2029. Table 8.13 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Revenue ($bn) 0.08 0.09 0.10 0.11 0.12 0.13 0.15 0.16 0.18 0.20 0.22 0.25 Annual Growth % 9.16% 9.26% 9.51% 9.77% 10.03% 10.31% 10.59% 10.88% 11.18% 11.49% 11.81% CAGR (%, 2019-24 & 24-29) 9.77% 11.19% CAGR (%, 2019- 2029) 10.48% Source: Visiongain, 2019 Figure 8.14 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029 Source: Visiongain, 2019 8.4 Asia-Pacific mRNA Vaccines & Therapeutics Market Size and Forecast 2019-2029 The Asia-Pacific region consists of developed as well as developing countries such as China, India, and other Asia-Pacific countries. Most of the countries in this region are economically developing with increasing disposable income. Many multinational companies are heavily investing in this region. In addition, countries such as Japan are technologically advanced in terms of healthcare and medical research, which aids in market growth of this region. Rising number of 0.08 0.09 0.10 0.11 0.12 0.13 0.15 0.16 0.18 0.20 0.22 0.25 9.16% 9.26% 9.51% 9.77% 10.03%10.31%10.59%10.88%11.18%11.49%11.81% 0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00% 14.00% 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.00 0.05 0.10 0.15 0.20 0.25 0.30 AGR(%) Year Revenue($bn) Revenue $bn AGR (%)
  3. 3. www.visiongain.com/industries/pharma Page138 mRNA Vaccines and Therapeutics Market Forecast 2019- 2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy 10.2.2 Financial Overview Figure 10.2 Sangamo Therapeutics: Financial Overview, 2016-2018 Source: Annual Report and SEC Filings; Visiongain 2019 10.2.3 Strategic Developments Table 10.6 Recent Developments: Sangamo Therapeutics, Inc. Month & Year Approach Description April, 2019 Financing The company announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share. All of the shares are being sold by Sangamo. April, 2019 Capacity Expansion The company announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale 19.39 36.57 84.45 0 10 20 30 40 50 60 70 80 90 2016 2017 2018 Revenue($Million) Year

×